Who Generates Higher Gross Profit? Dr. Reddy's Laboratories Limited or Bausch Health Companies Inc.

Dr. Reddy's vs. Bausch Health: A Profit Battle

__timestampBausch Health Companies Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 2014600890000075801000000
Thursday, January 1, 2015785380000085403000000
Friday, January 1, 2016706300000092281000000
Sunday, January 1, 2017617600000078356000000
Monday, January 1, 2018602900000076304000000
Tuesday, January 1, 2019625100000083430000000
Wednesday, January 1, 2020577800000094009000000
Friday, January 1, 20216040000000103077000000
Saturday, January 1, 20225760000000113840000000
Sunday, January 1, 20236198000000202972000000
Monday, January 1, 2024163607000000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Giants: Gross Profit Showdown

In the competitive landscape of the pharmaceutical industry, Dr. Reddy's Laboratories Limited and Bausch Health Companies Inc. have been vying for supremacy in gross profit generation. Over the past decade, Dr. Reddy's has consistently outperformed Bausch Health, with a staggering 168% higher average gross profit. From 2014 to 2023, Dr. Reddy's gross profit surged from approximately $75.8 billion to an impressive $202.9 billion, marking a growth of over 167%. In contrast, Bausch Health's figures remained relatively stable, peaking at $7.85 billion in 2015 and maintaining an average around $6.3 billion. The data for 2024 is incomplete, but the trend is clear: Dr. Reddy's has established itself as a dominant force. This analysis highlights the importance of strategic growth and market positioning in achieving financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025